INSM vs RPRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Insmed Incorporated exhibits a weak deterministic health profile with a Piotroski F-Score of 3/9, indicating significant fundamental instability. While the company shows explosive revenue growth of 152.6%, this is offset by extreme valuation metrics (Price/Sales of 55.10) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider activity—including significant sales by the CEO and COO—suggests a high-risk speculative profile rather than a value-driven investment.
RPRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating average financial health without strong momentum. The stock is significantly overvalued, trading at $50.00 despite a Graham Number of $24.60 and an Intrinsic Value of $36.49. Aggressive insider selling by the CFO and a sharp decline in recent Q/Q EPS growth (-67.5%) signal significant internal caution. While analyst sentiment remains a 'buy', the deterministic data and valuation gap suggest a high risk of a price correction.
Compare Another Pair
Related Comparisons
INSM vs RPRX: Head-to-Head Comparison
This page compares Insmed Incorporated (INSM) and Royalty Pharma plc (RPRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.